PRECISION MEDICINE · GLENVIEW, ILLINOIS

Decoding the Biology of
Race, Ciliary Signaling,
and Inflammatory
Disease - Through AI/ML

McGenome LLC develops AI/ML-powered molecular diagnostic and therapeutic platforms at the intersection of genomics, pathogen biology, and precision medicine — translating C. elegans and human cell science into tools that serve patients most underserved by existing standards. Four patent-pending platforms. One founding mission.

ELEGANS-INTERACTOMEPatent Pending · US 64/096,508
SarcoActivity™Patent Pending · US 64/078,909
KIF7-CilioPanel™Patent Pending · US 64/085,517
nmMLCK PlatformPatent Pending · US 64/084,368
NIH SBIR/STTRPhase I Applications in Preparation · NHLBI · NIMHD · NICHD
Published ScienceAlafghani et al. · Human Genomics · 2026
Patent-Pending Platforms

Four Platforms. Four Unmet Needs.

Developed from nearly five decades of C. elegans and human cell biology — translated into AI/ML diagnostic, therapeutic, and pathogen-interaction discovery platforms for the diseases and populations most underserved by existing science.

Pathogen Biology · Human Disease · AI/ML Discovery

ELEGANS-INTERACTOME

AI/ML Platform for Human Pathogen-Host Protein Interaction Discovery

ELEGANS-INTERACTOME is a Graph Neural Network (GNN) platform that predicts direct, physical protein-protein interactions between human pathogens and their human host targets — from pathogen protein sequence alone, without requiring prior experimental structural data.

The platform is anchored in a 50-year scientific tradition of Caenorhabditis elegans model biology. C. elegans shares more than 60% of human disease-gene orthologues and has been validated as a model host for bacterial, fungal, and viral pathogens including Pseudomonas aeruginosa, Staphylococcus aureus, Candida albicans, and multiple emerging infectious agents.

McGenome is actively developing research collaborations with leading C. elegans pathogen biology laboratories and human cell validation groups to provide experimental grounding for ELEGANS-INTERACTOME predictions.

Platform applications include:
  • Identification of novel pathogen virulence factors with human protein targets, including those with no prior structural characterization
  • Biodefense and biosurveillance: rapid characterization of emerging and engineered pathogen protein repertoires
  • Drug target discovery: prioritization of pathogen-human interaction nodes for small molecule and biologic therapeutic development
  • Antimicrobial resistance (AMR): pathway-level mapping of resistance-associated protein networks in priority pathogens
Patent Pending: US PPA No. 64/096,508 · Filed June 23, 2026
50-Year C. elegans Scientific FoundationC. elegans → Human Cell Experimental Validation PipelineBacterial · Fungal · Viral Pathogen Coverage
Explore ELEGANS-INTERACTOME →
Sarcoidosis · Health Equity

SarcoActivity™

Race-Calibrated AI Sarcoidosis Monitoring Platform

Serum ACE monitoring fails African American sarcoidosis patients due to two independent mechanisms: the rs1799752 II genotype polymorphism and ACE inhibitor pharmacological suppression - producing false-reassuring results in the population with 14× higher sarcoidosis mortality. SarcoActivity™ is a 7-component AI/ML platform providing race-calibrated composite disease activity monitoring, endotype classification, and drug response prediction.

US PPA No. 64/078,909 · Filed May 31, 2026 · Patent Pending
Academic and clinical validation in diverse sarcoidosis cohorts
7 components · 16 patent claims · BFD · SAI · FPP · MOEC · DRPE · NBDP · CDSS
Explore SarcoActivity™ →
Pediatric Rare Disease · Ciliopathy

KIF7-CilioPanel™

Molecular Diagnostic Platform for JSRD Ciliopathy

Joubert Syndrome and Related Disorders (JSRD) is a rare autosomal recessive ciliopathy affecting consanguineous populations globally, with a confirmed genetic diagnosis in fewer than 60% of patients using current single-gene testing. KIF7-CilioPanel™ is an 11-gene tiered NGS diagnostic platform combining functional Hedgehog pathway assays and the JCiloScore™ machine learning composite for JSRD diagnosis, prognosis, and organ surveillance planning.

US PPA No. 64/085,517 · Filed June 8, 2026 · Patent Pending
Alafghani et al. · Human Genomics · 2026 · Scientific Foundation
Validation in consanguineous Middle Eastern JSRD cohorts
Explore KIF7-CilioPanel™ →
ARDS · Vascular Leak · Therapeutics

nmMLCK Platform

AI/ML Precision Therapeutics Platform for ARDS

Acute Respiratory Distress Syndrome (ARDS) is a highly lethal critical care syndrome with no approved targeted pharmacotherapies. McGenome’s nmMLCK platform target-silences the endothelial-specific non-muscle myosin light chain kinase isoform (MLCK-L) to prevent microvascular barrier failure, utilizing a Neural ODE Digital Twin, GNN-RL siNA generative design, and lung-targeted LNPs.

US PPA No. 64/084,368 · Filed June 6, 2026 · Patent Pending
African ancestry-specific MYLK variant (rs117565355, rs80145233) design
5 components · Neural ODE Twin · GNN siNA generative design · Lung LNP
Explore nmMLCK Platform →
Academic & Research Home

McGenome LLC and the Niazee College of Osteopathic Medicine — Building the Science Together

ncomchicago.org →
COCA Candidate Status · Commission on Osteopathic College Accreditation · Opening 2027

Niazee College of Osteopathic Medicine (NCOM)

1300 E. Woodfield Road, Suite 650 | Schaumburg, IL 60173, USA

McGenome LLC's Founder and Chief Executive Officer, Shahid S. Siddiqui, Ph.D., holds the inaugural appointment of Chair and Professor of Foundational Biology at the Niazee College of Osteopathic Medicine (NCOM), Schaumburg, Illinois, effective July 1, 2026. At NCOM, Dr. Siddiqui is establishing a dedicated C. elegans and human cell wet laboratory — the experimental foundation that will support the ELEGANS-INTERACTOME platform and McGenome's broader research mission.

NCOM is a proposed osteopathic medical college in Candidate Status with the Commission on Osteopathic College Accreditation (COCA), preparing to train the next generation of compassionate, community-centered osteopathic physicians. Its research mission — identifying and igniting pioneering research enhancing osteopathic medicine and beyond — aligns directly with McGenome's focus on AI/ML-driven molecular diagnostics and pathogen-host interaction discovery in service of underserved patient populations.

The McGenome–NCOM partnership brings together 50 years of C. elegans and human cell research with the educational mission of a new osteopathic college dedicated to health equity, precision medicine, and whole-person care. The wet laboratory being established at NCOM will provide the in vivo experimental validation infrastructure for McGenome's computational platforms — closing the loop between AI-driven prediction and biological discovery.

Academic Chair

Chair & Professor of Foundational Biology NCOM, Schaumburg, Illinois | Effective July 1, 2026

Wet Lab Infrastructure

C. elegans & Human Cell Wet Laboratory being established at NCOM — experimental backbone of McGenome's AI/ML platforms

Mission Alignment

Community-centered precision medicine · Health equity · Osteopathic whole-person care

Candidacy Status

COCA Candidate Status · Pre-accreditation site visit July 2026 · Opening 2027 · 501(c)(3) not-for-profit

50

Years of Published C. elegans Science

Peer-reviewed research spanning C. elegans developmental genetics, kinesin motor biology, ciliary signaling, and human cell disease models — from the first C. elegans meeting at Woods Hole (1977) through the present.

4

Patent-Pending Platforms

Four AI/ML molecular medicine platforms filed at USPTO in 2026 — SarcoActivity™ (US 64/078,909), KIF7-CilioPanel™ (US 64/085,517), nmMLCK Platform (US 64/084,368), and ELEGANS-INTERACTOME (US 64/096,508).

NIH SBIR/STTR

Phase I Applications in Preparation · NHLBI · NIMHD · NICHD

Phase I STTR and SBIR applications in preparation, translating McGenome's four patent-pending platforms into clinical and commercial realities.